Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System

Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System

<b>Background</b>: Diabetic ketoacidosis (DKA), a life-threatening complication, can occur in individuals with type 2 diabetes during illness, stress, or medication use. This study examines DKA signals in type 2 diabetes, focusing on sodium–glucose cotransporter-2 (SGLT2) inhibitors, glu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hilal A. Thaibah, Otilia J. F. Banji, David Banji, Thamir M. Alshammari
Format:	Article
Language:	English
Published:	MDPI AG 2025-02-01
Series:	Pharmaceuticals
Subjects:	diabetic ketoacidosis (DKA) FDA adverse event reporting system (FAERS) hypoglycemic agents real-world evidence (RWE) SGLT2 inhibitors
Online Access:	https://www.mdpi.com/1424-8247/18/2/214
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024-11-01)

Elevated Leukocyte Glucose Index (LGI) Is Associated with Diabetic Ketoacidosis (DKA) Severity and Presence of Microvascular Complications
by: Mircea Cătălin Coșarcă, et al.
Published: (2025-05-01)

Characterisation of diabetic ketoacidosis in children and adolescents with type 1 diabetes: a regional hospital study
by: Sophy Korula, et al.
Published: (2025-06-01)

Low dose insulin infusion versus the standard dose in children with diabetic ketoacidosis: a meta-analysis
by: Mohamed Mohamed Belal, et al.
Published: (2024-12-01)

Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
by: Hilal A. Thaibah, et al.
Published: (2025-06-01)

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
by: Abhishek Kansara, et al.
Published: (2022-09-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Clinical and biochemical determinants of length of stay, readmission and recurrence in patients admitted with diabetic ketoacidosis
by: Fateen Ata, et al.
Published: (2023-12-01)

Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01)

Drug-induced cardiac arrest: a pharmacovigilance study from 2004–2024 based on FAERS database
by: Gaocan Ren, et al.
Published: (2025-05-01)

Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004–2024)
by: Yang Yang, et al.
Published: (2025-04-01)

Risk assessment of the top 50 drugs associated with drug-induced orthostatic hypotension: a disproportionality analysis of the FAERS and JADER databases
by: Gaocan Ren, et al.
Published: (2025-03-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Association between bipolar disorder and diabetic ketoacidosis/hyperosmolar hyperglycemic state
by: Han-Jung Liu, et al.
Published: (2025-07-01)

Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network
by: Yang Gao, et al.
Published: (2025-01-01)

A case of perioperative euglycemic ketoacidosis in a patient without diabetes: are current guidelines enough?
by: Shushmita Hoque, et al.
Published: (2025-07-01)

Mottling as an early sign of euglycemic ketoacidosis induced by SGLT-2 inhibitors
by: Besard Memeti, et al.
Published: (2025-03-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Resolution based on the results of the III annual scientific and practical conference «Real clinical practice in a changing world. Challenges and Solutions»
by: A. S. Kolbin
Published: (2022-11-01)

Resolution based on the results of the IV annual scientific-practical conference "Real clinical practice. Modernity and the future"
by: A. S. Kolbin
Published: (2023-12-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

HARPER — protocol template for real-world trials for evaluating treatment efficacy
by: S. M. Mukhina, et al.
Published: (2023-01-01)

Real-world evidence market: key players and key segments
by: A. R. Kasimova, et al.
Published: (2022-01-01)

Safety assessment of deutetrabenazine: real-world adverse event analysis from the FAERS database
by: Yanping Shu, et al.
Published: (2024-12-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

Evaluation of post-market adverse events of lubiprostone: a real-world adverse event analysis from the FAERS database
by: Qingqing Li, et al.
Published: (2025-05-01)

SGLT‐2 inhibitors and high‐dose acarbose as potential high‐risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series
by: Wei Qiang, et al.
Published: (2024-09-01)

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
by: Yongfu Song, et al.
Published: (2025-03-01)

Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology
by: Caitlin Clunie-O’Connor, et al.
Published: (2025-07-01)

Educational pharmacoepidemiology and "Real-World Knowledge"
by: R. A. Bontsevich
Published: (2025-01-01)

Resolution based on the results of the conference: "RWD/ RWE – Research Tools of Real-World Clinical Practice Today and Tomorrow"
by: A. S. Kolbin
Published: (2021-08-01)

Review of data sources used in real-world traumatology and orthopedic
by: I. U. Zolotukhina, et al.
Published: (2023-12-01)

ICH Reflection paper on proposed international harmonization of real-world evidence terminology and convergence of general principles regarding planning and reporting of studies using real-world data, with a focus on effectiveness of drugs
by: K. S. Radaeva, et al.
Published: (2023-10-01)

Re-starting or initiating guideline-recommended hypoglycemic agents for patients admitted with hyperglycemic crisis
by: Abdulrahman I. Alshaya, et al.
Published: (2025-08-01)

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
by: Yuan-Yuan Wu, et al.
Published: (2025-05-01)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
by: Sentai Wang, et al.
Published: (2025-03-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Research Priorities for Diabetic Ketoacidosis: An Evidence and Gap Mapping Review
by: Nicolas Sieben, et al.
Published: (2025-05-01)

Perioperative prevention of euglycaemic diabetic ketoacidosis in people living with type 2 diabetes established on sodium-glucose transport-2 inhibitors – a cross-site multi-cycle audit
by: Karl A. Romain, et al.
Published: (2025-09-01)

Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database
by: Jinlong Huang, et al.
Published: (2025-04-01)